Main menu

Mary Duseau, Paul Thomas

Jan 18, 2017

Roka Biosciences, a manufacturer of molecular diagnostics for foodborne pathogens, has named Mary Duseau as president and CEO. She succeeds Paul Thomas, who held those posts since 2009 and will now serve as chairman of the firm's board of directors. Duseau has been senior vice president and chief commercial officer at Roka since 2015. She was previously global sales director at Andor Technologies, a division of Oxford Instruments, and held various sales and management positions at PerkinElmer between 2000 and 2012.

More Like This

Mar 16, 2018

Gerald Herman

Bruker has appointed Gerald Herman as interim CFO effective March 17. Herman was also recently appointed as principal accounting officer for the company, and he will assume his additional responsibilities as interim CFO following the departure of current CFO Anthony Mattacchione, whose resignation was announced in February. Herman joined the company in 2016 as vice president and corporate controller. Prior to that, he held senior executive positions with various publicly traded companies including Parexel International and Presstek.

Mar 12, 2018

Phil Febbo

Illumina has appointed Phil Febbo as chief medical officer. Starting March 26, 2018, Febbo will be responsible for developing and executing on Illumina's strategy to drive genomic testing into healthcare practice.

Prior to Joining Illumina, Febbo has served as CMO at Genomic Health, and before that he served as professor of medicine and urology at the University of California, San Francisco, where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer. While at UCSF, Febbo was the co-leader of the Prostate Cancer Program at the Helen Diller Family Comprehensive Cancer Center and the Program Principal Investigator of the Translational Research Program for the Alliance for Clinical Trials in Oncology. He holds a BA degree in biology from Dartmouth College, received his MD at UCSF, and completed his internal medicine residency at the Brigham and Women's Hospital.

Mar 12, 2018

Rob Brainin, Hannes Smàrason

Rob Brainin has been appointed as WuXi NextCode's CEO, replacing Hannes Smàrason, who will stay on as a senior advisor and plans to pursue other entrepreneurial opportunities. Most recently, Brainin was the firm's executive vice president and COO. Prior to that, he held positions at Illumina, Thermo Fisher, Life Technologies, and Invitrogen. Brainin holds a degree in economics from Emory University and a JD degree from Harvard Law School.

Mar 08, 2018

Arne Materna

CosmosID announced today that it appointed Arne Materna as its VP of product. Materna previously worked at Qiagen, where he directed the product management organization responsible for a high-growth segment of Qiagen's portfolio of bioinformatics products. Prior to Qiage, Materna held managment and senior roles at CLC bio, Pacific Biosciences, and MIT.

Mar 07, 2018

David Cameron

Former UK prime minister David Cameron became a consultant for Illumina last month in order to help the company raise awareness about the benefits of genomics. Prior to his appointment, Cameron told the UK's Advisory Committee on Business Appointments that his main role would be to assist Illumina's engagement with foreign governments and stakeholders as it works and expands outside the UK, and that he would help with the formation of a new international advisory board and chair that board, which has not been established yet.

Mar 07, 2018

John Mattick

Genomics England has appointed John Mattick as its first CEO. Mattick will join Genomics England in June from Australia's Garvan Institute of Medical Research, which he has led since 2012. Mattick is noted for his scientific contributions to understanding the human genome, specifically his work showing that most of the genome is not evolutionary 'junk' but instead is devoted to an extensive RNA regulatory system that organizes human development. He will continue his academic career while in the UK at the University of Oxford's Green Templeton College, where he has been elected to a senior research fellowship for one day a week.

Mar 07, 2018

Paul Limburg

Exact Sciences has appointed Paul Limburg as co-chief medical officer. Limburg is a gastroenterologist and a professor of medicine at the Mayo Clinic, and serves as a co-leader of the Cancer Prevention and Control program within the Mayo Clinic Cancer Center. While at Mayo, he has also served as medical director of its global business solutions unit, and as medical director of several of its health and well-being programs. Limburg will advise Exact Sciences on research opportunities to inform, expand, and accelerate the adoption of effective colon cancer screening options such as Cologuard. He will continue to serve as a gastroenterologist with Mayo Clinic's Division of Gastroenterology and Hepatology, co-leader of the Cancer Prevention and Control program within Mayo Clinic Cancer Center, and principal investigator for the NCI-funded cancer prevention network clinical trials consortium.

Mar 02, 2018

Kim Albizati

Molecular Assemblies has appointed Kim Albizati as VP of chemistry and biochemistry. Prior to Molecular Assemblies, Albizati served senior direcctor of chemistry, manufactoring, and controls at Dart Neuroscience. In addition, Albizati has served as executive director of chemistry at Agouron and leadership positions at Pfizer.

Mar 01, 2018

Guillaume Bouhours

BioMérieux has appointed Guillaume Bouhours as corporate vice-president, CFO, and a member of its executive committee. He replaces Claire Giraut, who is retiring, and will head the firm's finance, purchasing, and information systems departments. Bouhours was previously CFO at Faiveley Transport, a railway equipment manufacturer based in France.

Mar 01, 2018

Jeffrey Mitchell

LexaGene Holdings has appointed Jeffrey Mitchell as its chief financial officer effective immediately.

Mitchell has more than two decades of financial and SEC experience, LexaGene said. Before joining the firm, he served in positions of increasing responsibility for Palomar Medical Technologies, including controller, director of finance, and supervisor of public-company financial reporting, audits, and financial planning and analysis.

He replaced Zula Kropivnitski.

Mar 01, 2018

Frank Williams

Frank Williams, cofounder and CEO of value-based care management company Evolent Health, has been named to the board of directors of precision oncology technology vendor Syapse. Syapse said that Williams, a former CEO of the Advisory Board Company, will be able to offer strategic advice as the company expands its reach. Since late November, Syapse has raised $30 million in new investment, hired a new VP of oncology, entered into a partnership with Roche, and entered the Asian market.

Feb 28, 2018

Jon Faiz Kayyem

GenMark Diagnostics' Founder Jon Faiz Kayyem is transitioning from his position as head of R&D to become a technical and strategic advisor to its management team and board of directors. Kayyem is the inventor of the firm's eSensor electronic detection technology and led the development of its ePlex multiplex platform. Kayyem noted during a company presentation Tuesday that he will now "endeavor to add value in new ways beyond ePlex."

Feb 23, 2018

Gianluca Pettiti

Gianluca Pettiti has become president of the biosciences business of Thermo Fisher Scientific's Life Sciences Solutions segment. Previously, he was the company's president in Greater China. He joined the firm in 2006 as senior manager of financial planning and analysis for Applied Biosystem's Europe, Middle East, and Africa region. He later became EMEA finance director and then president of Latin America operations at Life Technologies. Pettiti holds a master's degree in management and financial engineering from the Polytechnic University of Turin in Italy.

Feb 22, 2018

Clive Brown

Clive Brown's appointment as director of Oxford Nanopore Technologies ended on Jan. 25, the company said in a filing this week. He is the firm's chief technology officer. Brown was appointed as a company director in September 2017.

Feb 21, 2018

Anthony Mattacchione, Gerald Herman

Bruker said that Anthony Mattacchione will resign as chief financial officer and senior VP, effective Mar. 16, 2018. Mattacchione has accepted a position as CFO of Albany Molecular Research, commencing in April 2018. Gerald Herman, currently vice president and corporate controller at Bruker, will also serve as Bruker's principal accounting officer, effective immediately. Herman joined the firm in 2016 as VP and corporate controller. Prior to that, he served as corporate VP of clinical operations of Parexel from 2014 to February 2016, and before that, corporate VP of Parexel from 2008 to 2013. Herman has also served as VP-corporate controller of Presstek.